Back to News list
Nanoportal Biotech Showcases Innovative Non-Viral Delivery Platforms at ASGCT 2026
News

Nanoportal Biotech Showcases Innovative Non-Viral Delivery Platforms at ASGCT 2026

2026.06.10

BOSTON, MA — Nanoportal Biotech, a pioneer in biomimetic delivery technologies, presented its breakthrough non-viral delivery platforms at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, held from May 11–15, 2026, in Boston.

 

At this year’s meeting, Nanoportal highlighted its proprietary EASY (Endogenous coacervAte-baSed deliverY) platform. Designed to overcome the historical bottlenecks of primary cell engineering—such as low efficiency, complex workflows, and cellular toxicity—EASY leverages natural liquid-liquid phase separation (LLPS) to establish a highly efficient, non-viral, non-lipid, and electroporation-free delivery route.

 

Presentation Highlights

Special Forum Feature: ProteanFect

  • Title: ProteanFect: The First      Protein-based Transfection Solution for Efficient Gene Modulation in      Primary Cells

  • Time: May 13 | 3:15 PM - 3:30 PM      (EST)

  • Location: Exhibition Hall

Poster Session

  • Abstract / Poster #: 3109

  • Title: Bio-inspired, endogenous      coacervate–based platform for efficient gene editing in primary cells

  • Time: May 14 | 5:00 PM - 6:30 PM      (EST)

  • Location: Convention Center, Poster      Hall

 

Core Technological Advantages

During the presentation sessions, the Nanoportal team shared robust data demonstrating the EASY platform's performance across clinically relevant, "tough-to-transfect" cell types (Primary T cells, NK cells, HSCs, and iPSCs):

  • Ultra-Streamlined Workflow:      Requires only a 1-minute formulation prep and a 15-minute      incubation to complete transfection. The platform supports seamless      scalability from 10^4 up to 10^9 cells, making it fully compatible with      commercial clinical manufacturing.

  • High-Efficiency Knockout (KO):      Achieved ~80% TRAC knockout in primary T cells, with robust      capacity for simultaneous multiplexed editing (TRAC/B2M/PDCD1).

  • Precision Targeted Integration (Knock-in): Enabled precise, non-viral site-specific integration of an      anti-CD19 CAR cassette into the TRAC locus via Cas9 RNP and DNA      template co-delivery. The resulting CAR-T cells demonstrated potent      anti-tumor efficacy in vitro and in vivo.

  • Next-Gen Editing Compatibility:      Demonstrated ~55% Prime Editing (PE) efficiency in iPSCs while maintaining      exceptional cell viability.